Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders [Yahoo! Finance]
Centessa Pharmaceuticals plc - American Depositary Shares (CNTA)
Company Research
Source: Yahoo! Finance
Acquisition expands Lilly's neuroscience portfolio and capabilities into sleep medicine INDIANAPOLIS and BOSTON and LONDON March 31, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other neurological conditions, today announced a definitive agreement for Lilly to acquire Centessa. Centessa is advancing a pipeline of orexin receptor 2 (OX2R) agonists designed to address the neurobiological system critical to the sleep-wake cycle to treat excessive daytime sleepiness and disorders of impaired wakefulness. Its lead investigational candidate cleminorexton (formerly ORX750) has demonstrated a potential best-in-class profile in Phase 2a clinical studies across narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia. Centessa's OX2R agonist portfolio includes additional clinical and preclinical-stage assets wi
Show less
Read more
Impact Snapshot
Event Time:
CNTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CNTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CNTA alerts
High impacting Centessa Pharmaceuticals plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
CNTA
News
- Centessa Pharmaceuticals (CNTA) had its "neutral" rating reaffirmed by Guggenheim.MarketBeat
- Centessa Pharmaceuticals (CNTA) was downgraded by B. Riley Financial, Inc. from "strong-buy" to "hold".MarketBeat
- Centessa Pharmaceuticals (CNTA) was downgraded by Lifesci Capital from "strong-buy" to "hold".MarketBeat
- Centessa Pharmaceuticals (CNTA) had its "market perform" rating reaffirmed by Leerink Partners. They now have a $40.00 price target on the stock, up from $36.00.MarketBeat
- SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Centessa Pharmaceuticals plc (NASDAQ: CNTA)PR Newswire
CNTA
Earnings
- 3/31/26 - Miss
CNTA
Sec Filings
- 3/31/26 - Form DEFA14A
- 3/31/26 - Form DEFA14A
- 3/31/26 - Form DEFA14A
- CNTA's page on the SEC website